Eyerising International
Eyerising International is an Australian MedTech company developing life-impacting eye-health therapy to slow the progression of myopia. The Eyerising Myopia Management Device delivers repeated low-level red-light therapy to the back of the eye, where it stimulates blood flow and thickens the layer of the back of the eye known as the choroid. This helps to slow further elongation of the eye’s axial length and thereby control myopia progression.
Eyerising International sponsored articles.
Eyerising International myopia management products
Myopia management products listed by Myopia Profile have been specifically designed for myopia control or myopia management in children, and have some form of regulatory approval or marking for this form of use. They also have randomized controlled trial research data supporting their efficacy, unless otherwise noted. It is up to the individual eye care practitioner to be aware of regulatory requirements for prescribing in their country of practice, and also be aware that not all products are available in all countries.
Eyerising Myopia Management Device
The Eyerising Myopia Management Device delivers Repeated Low-Level Red-Light (RLRL) therapy to the ocular fundus through semi-conductor laser diodes emitting 650nm visible red light. The Eyerising device has been demonstrated to increase choroidal blood flow and induce choroidal thickening, potentially addressing the scleral hypoxia implicated in myopia progression. It is backed by over 40 clinical studies, including 2-year clinical trial results showing myopia control efficacy.
Eyerising International resources
Eyerising Expert Video Interview Series Highlights
Eyerising International recently undertook a series of video interviews where global experts spoke to Dr Kate Gifford of Myopia Profile about their clinical experiences, observations and work with the Eyerising Myopia Management Device.